Tu1741 – A Novel Oral Formulation of Budesonide is Effective for Induction of Remission in Mesalamine Refractory Ulcerative Colitis (TOPICAL-1)
Klaus Fellermann(Apple (Israel)), Roland Greinwald(Dr Falk Pharma (Germany)), I Rácz(Petz Aladár Megyei Oktató Kórház), Jeļena Derova(Latvian Maritime Academy), Ingolf Schiefke(University Hospital Leipzig), Laimas Virginijus Jonaitis(Lithuanian University of Health Sciences), Tanju Nacak(Dr Falk Pharma (Germany))
Cited by 0
Related Papers
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
|Endoscopy|2015|823
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566